CMS-121 (C09-1119-637)

CMS-121 is a quinolone derivative and an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage with EC 50 values of 7 nM and 200 nM, respectively. CMS-121 has strong neuroprotective, anti-inflammatory, antioxidative and renoprotective activitiesIn VitroCMS-121 (1 µM; 4 hours; HT22 cells) treatment increases the phosphorylation of ACC1 at serine 79. CMS-121 can increase acetyl-CoA in cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: HT22 cells Concentration: 1 µM Incubation Time: 4 hours Result: Increases the phosphorylation of ACC1 at serine 79.In VivoCMS-121 (~20 mg/kg; oral administration; daily; for 4 months; female SAMP8 mice) treatment reduces cognitive decline as well as metabolic and transcriptional markers of aging in the brain when administered to rapidly aging SAMP8 mice. CMS-121 preserves mitochondrial homeostasis by regulating acetyl-coenzyme A (acetyl-CoA) metabolism . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female SAMP8 mice (9 months old) Dosage: ~20 mg/kg/day Administration: Oral administration; daily; for 4 months Result: Reduced cognitive decline as well as metabolic and transcriptional markers of aging in the brain.Form:SolidIC50& Target:Acetyl-CoA carboxylase 1 (ACC1). Specification: 0.98 Molecular Formula: C20H19NO3 Molecular Weight: 321.37 PubChem CID: 135741221 Isomeric SMILES: C1CCC(C1)OC2=CC(=NC3=CC=CC=C32)C4=CC(=C(C=C4)O)O